Onconetix, Inc. Noncash or Part Noncash Acquisition, Payables Assumed
Onconetix, Inc. (ONCO) reported Noncash or Part Noncash Acquisition, Payables Assumed of $150.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-06-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2025-06-02
- Onconetix, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-12-31 was $0.00.
- Onconetix, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-09-30 was $0.00.
- Onconetix, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-06-30 was -$189.59K.
- Onconetix, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2023-03-31 was $339.59K.
- Onconetix, Inc. noncash or part noncash acquisition, payables assumed for fiscal 2023 was $150.00K.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 3 month | Noncash or Part Noncash Acquisition, Payables Assumed 6 month | Noncash or Part Noncash Acquisition, Payables Assumed 9 month | Noncash or Part Noncash Acquisition, Payables Assumed 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $0.00 derived: sum of 2 quarters · filed 2025-06-02 | -$189.59K derived: sum of 3 quarters · filed 2025-06-02 | $150.00K 10-K · filed 2025-06-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | -$189.59K derived: sum of 2 quarters · filed 2024-12-10 | $150.00K 10-Q · filed 2024-12-10 | |
| 2023-06-30 | -$189.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | $150.00K 10-Q · filed 2024-08-29 | ||
| 2023-03-31 | $339.59K 10-Q · filed 2024-05-20 | |||
| 2022-09-30 | -$62.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $125.00K 10-Q · filed 2023-11-17 | ||
| 2022-06-30 | $187.50K 10-Q · filed 2023-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |